The high atherogenic potential of the @entity1720 can be only partly explained by the association of "classical" risk factors of @entity731 which are considered part of it, i.e. impaired @entity1735 tolerance/ @entity6 , dyslipidaemia, @entity101 and @entity28 . Impaired fibrinolysis due to excessive production of the @entity2289 ( @entity2289 ) are further risk factors which participate in the process of atherogenesis from the beginning of formation of the @entity1856 plaque to the @entity715 occlusion of the vascular lumen. The authors present a group of 25 @entity1 with different grades of @entity413 resistance, evaluated by theinsulin response to a @entity413 load. The insulin resistant group (n = 15) differed significantly from the non-resistant one (n = 10) as regards body weight and the central type of @entity28 (< 0.01 and 0.001 resp.) insulin level on fasting and after a load (< 0.0001 and 0.001 resp.), @entity412 levels (< 0.01), the incidence of @entity6 or impaired @entity1735 tolerance (66.7 vs. 20%) and @entity101 (53.3 vs. 20%), but also as regards the @entity2289 activity (.0001). As regards blood sugar levels, total and HDL @entity165 the groups did not differ. The authors investigated also the relationship between @entity2289 activity and different components of the @entity1720 in the whole group. The closest correlation was found between the @entity2289 activity and the general insulinaemic response to a @entity413 load (< 0.001) and between @entity2289 and @entity1674 (< 0.001). Based on the presented results it may be stated that hypofibnrinolysis as a result of excessive production of @entity2289 is part of the @entity1720 and potentiates its high atherogenic risk.

[The XXXX and fibrinolysis disorders].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2289 :: ('5054', 'Gene') :: ['plasminogen activator inhibitor-1', 'PAI.1', 'PAI-1'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus type II', 'diabetes'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity1735 :: ('CHEBI:16646', 'Chemical') :: ['carbohydrate'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity1856 :: ('MESH:D058226', 'Disease') :: ['atheromatous'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis'] @entity1720 :: ('MESH:D007333', 'Disease') :: ['insulin resistance syndrome'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity1720 :: (MESH:D007333,Disease) :: ['insulin resistance syndrome']
